| Literature DB >> 35818022 |
Pedro Cortés1, Hassan M Ghoz2, Fernando Stancampiano1, Mohamed Omer2, Balkishan Malviya2, Andrew W Bowman3, William C Palmer4.
Abstract
BACKGROUND: Incidentalomas, defined as incidental findings on imaging, are a growing concern. Our aim was to determine the impact and outcomes of extrahepatic incidentalomas on liver transplantation.Entities:
Keywords: Incidentaloma; Liver cirrhosis; Liver transplantation; MRI screening; Management
Mesh:
Year: 2022 PMID: 35818022 PMCID: PMC9275240 DOI: 10.1186/s12876-022-02379-7
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 2.847
Baseline Characteristics of All Patients
| Variables | N = 720 |
|---|---|
| Age, year (mean, SD) | 57.7 (12.1) |
| Male Sex, % | 450 (62.5%) |
| BMI, kg/m2, (mean, SD) | 29.4 (6.3) |
| Obesity, % | 285 (39.6%) |
| White, % | 636 (88.3%) |
| African American, % | 32 (4.4%) |
| Asian, % | 17 (2.4%) |
| Other Race, % | 35 (4.9%) |
| Hispanic/Latino, % | 48 (6.7%) |
| History of Moderate Alcohol Use, % | 142 (19.7%) |
| Ever smoked, % | 399 (55.4%) |
| Current smoker, % | 19 (2.6%) |
| Sodium, mmol/L (mean, SD) | 138 (4.1) |
| Total Bilirubin, mg/dL (mean, SD) | 2.7 (4.2) |
| INR, (mean, SD) | 1.4 (0.4) |
| Creatinine, mg/dL (mean, SD) | 1.0 (0.5) |
| MELD, (mean, SD) | 14.4 (6.9) |
| MELD ≥ 18, % | 201 (27.9%) |
| MELD ≥ 26, % | 49 (6.8%) |
| A1AT Deficiency, % | 17 (2.4%) |
| Alcohol, % | 148 (20.6%) |
| Autoimmune, % | 45 (6.3%) |
| Cryptogenic, % | 49 (6.81%) |
| Hemochromatosis, % | 9 (1.3%) |
| Hepatitis B, % | 18 (2.5%) |
| Hepatitis C, % | 159 (22.1%) |
| NASH, % | 179 (24.9%) |
| Other, % | 16 (2.2%) |
| Primary Biliary Cirrhosis, % | 32 (4.4%) |
| Primary Sclerosing Cholangitis, % | 45 (6.3%) |
| Wilson’s Disease, % | 3 (0.4%) |
| History of prior TIPS | 38 (5.3%) |
| Incidentaloma Discovered | 574 (79.7%) |
| Transplanted at End of Study | 532 (73.9%) |
SD standard deviation, BMI body mass index, INR international standardized ratio, MELD model for end-stage liver disease, A1AT alpha-1 antitrypsin, NASH non-alcoholic steatohepatitis TIPS transjugular intrahepatic portosystemic shunt
Baseline characteristics according to if incidentaloma was discovered on MRI surveillance for HCC
| Incidentaloma Absent N = 146 | Incidentaloma Discovered N = 574 | ||
|---|---|---|---|
| Age, year (mean, SD) | 50.5 (15.5) | 59.6 (10.2) | |
| Male Sex, % | 85 (58.2%) | 365 (63.6%) | 0.2312 |
| BMI, kg/m2, (mean, SD) | 28.6 (6.6) | 29.6 (6.2) | 0.08481 |
| Obesity, % | 56 (38.4% | 229 (39.9%) | 0.7342 |
| White, % | 126 (86.3%) | 510 (88.9%) | 0.3922 |
| African American, % | 7 (4.8%) | 25 (4.4%) | 0.8223 |
| Asian, % | 4 (2.7%) | 13 (2.3%) | 0.7603 |
| Other Race, % | 9 (6.2%) | 26 (4.5%) | 0.3933 |
| Hispanic/Latino, % | 10 (6.8%) | 38 (6.6%) | 0.8553 |
| History of Moderate Alcohol Use, % | 25 (17.1%) | 117 (20.4%) | 0.3772 |
| Ever smoked, % | 73 (50.0%) | 326 (56.8%) | 0.1402 |
| Current smoker, % | 6 (4.1%) | 13 (2.3%) | 0.2443 |
| Sodium, mmol/L (mean, SD) | 137.5 (3.9) | 138.1 (4.1) | 0.14031 |
| Total Bilirubin, mg/dL (mean, SD) | 3.5 (5.4) | 2.5 (3.8) | |
| INR, (mean, SD) | 1.4 (0.5) | 1.4 (0.4) | 0.53121 |
| Creatinine, mg/dL (mean, SD) | 1.0 (0.6) | 1.0 (0.5) | 0.67001 |
| MELD, (mean, SD) | 15.1 (7.2) | 14.2 (6.9) | 0.17641 |
| MELD ≥ 18, % | 47 (32.2%) | 154 (26.8%) | 0.2152 |
| MELD ≥ 26, % | 12 (8.2%) | 37 (6.4%) | 0.4623 |
| Etiology of Cirrhosis | 0.9312 | ||
| NASH, % | 31 (21.2%) | 148 (25.8%) | 0.2562 |
| Hepatitis C, % | 29 (19.9%) | 130 (22.6%) | 0.4692 |
| Alcohol, % | 28 (19.2%) | 120 (20.9%) | 0.6452 |
| History of prior TIPS | 7 (4.8%) | 31 (5.4%) | 1.0003 |
| Transplanted at end of study | 98 (67.1%) | 434 (75.6%) |
P values significant at p < 0.05 are bolded in the accompanying tables
MRI magnetic resonance imaging, HCC hepatocellular carcinoma, SD standard deviation, BMI body mass index, INR international standardized ratio, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, TIPS transjugular intrahepatic portosystemic shunt
1Student T test, independent samples, two-sided, equal variance not assumed
2Pearson’s Chi Square Test
3Fisher’s Exact Test
Baseline characteristics according to if liver transplantation was performed by the end of study period
| Not Transplanted N = 188 | Transplanted N = 532 | ||
|---|---|---|---|
| Age, year (mean, SD) | 59.2 (14.5) | 57.2 (11.0) | 0.07901 |
| Male Sex, % | 102 (54.3%) | 348 (65.4%) | |
| BMI, kg/m2, (mean, SD) | 29.3 (6.9) | 29.4 (6.0) | 0.77771 |
| Obesity, % | 74 (39.4%) | 211 (39.7%) | 0.9422 |
| White, % | 166 (88.3%) | 470 (88.3%) | 0.9862 |
| African American, % | 10 (5.3%) | 22 (44.1%) | 0.5373 |
| Asian, % | 5 (2.7%) | 12 (2.3%) | 0.7813 |
| Other Race, % | 7 (3.7%) | 28 (5.3%) | 0.5543 |
| Hispanic/Latino, % | 8 (4.3%) | 40 (7.5%) | 0.1723 |
| History of Moderate Alcohol Use, % | 29 (15.4%) | 113 (21.2%) | 0.085 |
| Ever smoked, % | 90 (47.9%) | 309 (58.1%) | |
| Current smoker, % | 19 (10.1%) | 0 (0.0%) | |
| Sodium, mmol/L (mean, SD) | 139.2 (3.0) | 137.5 (4.3) | |
| Total Bilirubin, mg/dL (mean, SD) | 1.3 (2.4) | 3.2 (4.5) | |
| INR, (mean, SD) | 1.2 (0.3) | 1.4 (0.5) | |
| Creatinine, mg/dL (mean, SD) | 1.0 (0.4) | 1.0 (0.6) | 0.18341 |
| MELD, (mean, SD) | 10.4 (4.3) | 15.8 (7.1) | |
| MELD ≥ 18 | 11 (5.9%) | 190 (35.7%) | |
| MELD ≥ 26 | 1 (0.5%) | 48 (9.0%) | |
| Etiology of Cirrhosis | 0.0562 | ||
| NASH, % | 52 (27.7%) | 127 (23.9%) | 0.3022 |
| Hepatitis C, % | 31 (16.5%) | 128 (24.1%) | |
| Alcohol, % | 29 (15.4%) | 119 (22.4%) | |
| History of prior TIPS | 6 (3.2%) | 32 (6.0%) | 0.1833 |
| Incidentaloma Discovered | 140 (74.5%) | 434 (81.6%) |
P values significant at p < 0.05 are bolded in the accompanying tables
MRI magnetic resonance imaging, SD standard deviation, BMI body mass index, INR international standardized ratio, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, TIPS transjugular intrahepatic portosystemic shunt
1Student T test, independent samples, two-sided, equal variance not assumed
2Pearson’s Chi Square Test
3Fisher’s Exact Test
Fig. 1Kaplan–Meier Estimates for being transplanted according to etiology of cirrhosis
Fig. 2Kaplan–Meier estimates for being transplanted according to incidentaloma being discovered
Univariate Cox proportional hazards regression analysis for predicting liver transplantation
| HR | 2.5% | 97.5% | p-value | |
|---|---|---|---|---|
| Age, per 1 year | 1.0000 | 0.9900 | 1.0100 | 0.9172 |
| Age [18,40) years | 0.9100 | 0.6800 | 1.2200 | 0.5397 |
| Age [40,50) years | 0.9000 | 0.6900 | 1.1800 | 0.4552 |
| Age [50,65) years | 1.1500 | 0.9700 | 1.3700 | 0.0993 |
| Age ≥ 65 years | 0.9300 | 0.7700 | 1.1200 | 0.9300 |
| Male Sex | 1.2800 | 1.0700 | 1.5300 | |
| BMI, per 1 kg/m2 | 0.9900 | 0.9800 | 1.0100 | 0.3536 |
| Obesity | 0.9500 | 0.8000 | 1.1300 | 0.5819 |
| White | 0.8800 | 0.6700 | 1.1400 | 0.3303 |
| African American | 0.8557 | 0.6300 | 1.4700 | 0.8557 |
| Asian | 0.9364 | 0.5800 | 1.8200 | 0.9364 |
| Other Race | 1.3800 | 0.9400 | 2.0200 | 0.0963 |
| Hispanic/Latino | 1.3600 | 0.9900 | 1.8800 | 0.0611 |
| History of Moderate Alcohol Use | 1.5200 | 1.2400 | 1.8800 | |
| Ever smoked | 1.2100 | 1.0200 | 1.4400 | |
| Sodium, per 1 mmol/L | 0.9300 | 0.9100 | 0.9500 | |
| Total Bilirubin, per 1 mg/dL | 1.1500 | 1.1300 | 1.1700 | |
| INR, per 1 point | 2.5300 | 2.1800 | 2.9400 | |
| Creatinine, per 1 mg/dL point | 1.3300 | 1.1500 | 1.5500 | |
| MELD, per 1 point | 1.1200 | 1.1100 | 1.1400 | |
| MELD ≥ 18 | 2.8309 | 2.3151 | 3.4616 | |
| MELD ≥ 26 | 2.5241 | 1.8162 | 3.5080 | |
| Etiology of Cirrhosis | 1.2900 | 1.1300 | 1.4600 | |
| NASH | 0.8300 | 0.6800 | 1.0100 | 0.0636 |
| Hepatitis C | 1.0700 | 0.8800 | 1.3100 | 0.5049 |
| Alcohol | 1.5600 | 1.2700 | 1.9100 | |
| History of prior TIPS | 1.1500 | 0.8000 | 1.6500 | 0.4422 |
| Incidentaloma Discovered | 1.3126 | 1.0858 | 1.5869 | |
P values significant at p < 0.05 are bolded in the accompanying tables
BMI body mass index, INR international standardized ratio, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, TIPS transjugular intrahepatic portosystemic shunt
Multivariate Cox proportional hazards regression analysis for predicting liver transplantation
| HR | 2.5% | 97.5% | ||
|---|---|---|---|---|
| Age, per 1 year | 1.0060 | 0.9983 | 1.0139 | 0.1277 |
| Male Sex | 1.0948 | 0.9095 | 1.3178 | 0.3384 |
| BMI, per 1 kg/m2 | 0.9973 | 0.9833 | 1.0166 | 0.7110 |
| White | 0.9540 | 0.7241 | 1.2570 | 0.7380 |
| Hispanic/Latino | 1.3141 | 0.9436 | 1.8302 | 0.1060 |
| History of Moderate Alcohol Use | 1.0178 | 0.8052 | 1.2865 | 0.8827 |
| Ever smoked | 1.1609 | 0.9656 | 1.3956 | 0.1125 |
| MELD, per 1 point | 1.1219 | 1.1060 | 1.1380 | |
| NASH | 0.9365 | 0.7464 | 1.1751 | 0.5712 |
| History of prior TIPS | 0.8839 | 0.6120 | 1.2766 | 0.5106 |
| Incidentaloma Discovered | 1.2975 | 1.0679 | 1.5763 | |
P values significant at p < 0.05 are bolded in the accompanying tables
BMI body mass index, MELD model for end-stage liver disease, NASH non-alcoholic steatohepatitis, TIPS transjugular intrahepatic portosystemic shunt
Types of extra-hepatic incidentalomas
| Patients with Incidentalomas, N = 574 | Total, % |
|---|---|
| Total number of Incidentalomas | 690 |
| Patients with multiple incidentalomas | 106 (18.5%) |
| Kidney | 420 (60.9%) |
| Pancreas | 208 (30.1%) |
| Spleen | 25 (3.6%) |
| Adrenal | 11 (1.6%) |
| Gallbladder | 11 (1.6%) |
| Pelvic | 9 (1.3%) |
| Bone | 4 (0.6%) |
| Stomach | 2 (0.3%) |
| Number of incidentalomas undergoing biopsy/resection | 16 (2.3%) |
| Pancreas | 7 (47.1%) |
| Kidney | 3 (17.6%) |
| Gallbladder | 4 (23.5%) |
| Pelvis | 1 (5.9%) |
| Stomach | 1 (5.9%) |
| Number of malignancies detected | 7 (1.0%) |
| Gastric Neuroendocrine Tumor | 1 (14.3%) |
| Cholangiocarcinoma | 2 (28.6%) |
| Renal cell carcinoma | 3 (42.9%) |
| Pancreatic adenocarcinoma | 1 (14.3%) |
| Observation | 682 (98.8%) |
| Surgery, alone | 5 (0.7%) |
| Chemotherapy/Radiation, alone | 2 (0.3%) |
| Surgery and Chemotherapy/Radiation | 1 (0.1%) |
Features of Kidney and Pancreatic Incidentalomas
| Incidentaloma, N = 690 | Total, % |
|---|---|
| Kidney or Pancreatic | 628 (91.0%) |
| Kidney | 420 |
| Simple Cyst | 417 (99.3%) |
| Solid Lesion | 3 (0.7%) |
| < 1 cm | 396 (94.3%) |
| [1,3) cm | 15 (3.6%) |
| [3, 5) cm | 3 (0.7%) |
| ≥ 5 cm | 6 (1.4%) |
| Referred to Urology | 5 (1.2%) |
| Pancreas | 208 |
| IPMN, Cystic Lesion | 207 (99.5%) |
| Solid Lesion | 1 (0.5%) |
| < 1 cm | 169 (81.3%) |
| [1,3) cm | 36 (17.3%) |
| [3, 5) cm | 2 (1.0%) |
| ≥ 5 cm | 1 (0.5%) |
| Referred to Gastroenterology | 109 (52.4%) |
| Underwent EUS | 12 (5.8%) |
IPMN intraductal papillary mucinous neoplasm, EUS endoscopic ultrasound
Features of pancreatic lesions that underwent endoscopic ultrasound
| MRI Findings | CA 19–9 (U/mL) | EUS Findings | Biopsy | Pathology |
|---|---|---|---|---|
| Numerous subcentimeter non-enhancing cysts, likely side-branch IPMNs | N/A | Mild-moderate chronic pancreatitis | No | N/A |
| 1.4 × 2.2 cm cystic lesion at pancreatic head, likely IPMN | 105 | Multicystic, septated, 22 × 15 mm lesion | Yes | Malignancy absent, mucinous epithelium |
| Multilobulated pancreatic tail cystic lesion, 2.4 × 2.9 cm | N/A | Septated lesion, 28 mm, side-branch IPMN | Yes | Malignancy absent, mucinous epithelium |
| Parenchymal atrophy, innumerable tiny cysts; irregular main duct | N/A | Many benign cysts in tail; largest 7 mm | No | N/A |
| 3.3 × 2.3 cm septated cystic lesion at pancreatic neck | 6 | Multiloculated 2.75 × 1.98 cm cyst at neck | Yes | Malignancy absent, mucinous epithelium |
| Numerous unilocular cysts at head, largest 14 mm | 255 | 12 × 10 mm cyst in pancreatic head | Yes | Malignancy absent, mucinous epithelium |
| 1.7 cm hypoenhancing head mass | 103 | 1.7 cm pancreatic head mass | Yes | Adenocarcinoma |
| 3 mm cystic lesion at uncinate process | N/A | 8 × 8 mm uncinate cystic lesion | No | N/A |
| Few sub-5 cm cystic foci in pancreas | 44 | Few cysts in the pancreatic head | No | N/A |
| 7–8 mm enhancing lesion at uncinate process, suspicious for NET | 35 | Multiple cystic lesions at uncinate, 10 × 10 mm | Yes | Malignancy absent, mucinous epithelium |
| Small cystic lesions, likely side-branch IPMNs | 29 | Pancreatic head cysts, 3 × 3 mm, no mass | No | N/A |
| Small cystic lesions, largest is 8 × 12 mm, likely IPMN | N/A | 25 × 17 mm pancreatic head cystic lesion | Yes | Malignancy absent, mucinous epithelium |
MRI magnetic resonance imaging; CA 19–9, carbohydrate antigen 19–9 (reference range: < 55 U/mL); EUS endoscopic ultrasound, N/A not available, NET neuroendocrine tumor, IPMN intraductal papillary mucinous neoplasm
Features of malignant incidentalomas
| Incidental Finding | Size | Pathology | Treatment | Transplanted |
|---|---|---|---|---|
| Gastric solid lesion | < 1 cm | Well-differentiated NET | EMR, Cured | No |
| Gallbladder solid lesion | 1–3 cm | Cholangiocarcinoma | Chemoradiation, Died | No |
| Renal solid lesion | > 5 cm | Renal cell carcinoma, clear cell | Nephrectomy, Cured | Yes |
| Gallbladder solid lesion | 1–3 cm | Cholangiocarcinoma | Neoadjuvant Chemotherapy, Cured with transplantation | Yes |
| Renal solid lesion | 1–3 cm | Renal cell carcinoma, papillary | Nephrectomy, Cured | Yes |
| Renal solid lesion | < 1 cm | Renal cell carcinoma, clear cell | Nephrectomy, Cured | Yes |
| Pancreatic solid lesion | 1–3 cm | Pancreatic adenocarcinoma | Chemotherapy and Surgery, Cured | No |
NET neuroendocrine tumor, EMR endoscopic mucosal resection